Rony Chanoch-Myers1, Adi Wider1, Mario L Suva2,3, Itay Tirosh4. 1. Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel. 2. Department of Pathology and Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA. 3. Broad Institute of MIT and Harvard, Cambridge, MA, USA. 4. Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel. itay.tirosh@weizmann.ac.il.
Abstract
BACKGROUND: Multiple glioblastoma studies have described a mesenchymal (MES) state, with each study defining the MES program by distinct sets of genes and highlighting distinct functional associations, including both immune activation and suppression. These variable descriptions complicate our understanding of the MES state and its implications. Here, we hypothesize that there is a range of glioma MES states, possibly reflecting distinct prior states in which a MES program can be induced, and/or distinct mechanisms that induce the MES states in those cells. METHODS: We integrated multiple published single-cell and bulk RNA sequencing datasets and MES signatures to define a core MES program that recurs across studies, as well as multiple function-specific MES signatures that vary across MES cells. We then examined the co-occurrence of these signatures and their associations with genetic and microenvironmental features. RESULTS: Based on co-occurrence of MES signatures, we found three main variants of MES states: hypoxia-related (MES-Hyp), astrocyte-related (MES-Ast), and an intermediate state. Notably, the MES states are differentially associated with genetic and microenvironmental features. MES-Hyp is preferentially associated with NF1 deletion, overall macrophage abundance, a high macrophage/microglia ratio, and M2-related macrophages, consistent with previous studies that associated MES with immune suppression. In contrast, MES-Ast is associated with T cell abundance and cytotoxicity, consistent with immune activation through expression of MHC-I/II. CONCLUSIONS: Diverse MES states occur in glioblastoma. These states share a subset of core genes but differ primarily in their association with hypoxia vs. astrocytic expression programs, and with immune suppression vs. activation, respectively.
BACKGROUND: Multiple glioblastoma studies have described a mesenchymal (MES) state, with each study defining the MES program by distinct sets of genes and highlighting distinct functional associations, including both immune activation and suppression. These variable descriptions complicate our understanding of the MES state and its implications. Here, we hypothesize that there is a range of glioma MES states, possibly reflecting distinct prior states in which a MES program can be induced, and/or distinct mechanisms that induce the MES states in those cells. METHODS: We integrated multiple published single-cell and bulk RNA sequencing datasets and MES signatures to define a core MES program that recurs across studies, as well as multiple function-specific MES signatures that vary across MES cells. We then examined the co-occurrence of these signatures and their associations with genetic and microenvironmental features. RESULTS: Based on co-occurrence of MES signatures, we found three main variants of MES states: hypoxia-related (MES-Hyp), astrocyte-related (MES-Ast), and an intermediate state. Notably, the MES states are differentially associated with genetic and microenvironmental features. MES-Hyp is preferentially associated with NF1 deletion, overall macrophage abundance, a high macrophage/microglia ratio, and M2-related macrophages, consistent with previous studies that associated MES with immune suppression. In contrast, MES-Ast is associated with T cell abundance and cytotoxicity, consistent with immune activation through expression of MHC-I/II. CONCLUSIONS: Diverse MES states occur in glioblastoma. These states share a subset of core genes but differ primarily in their association with hypoxia vs. astrocytic expression programs, and with immune suppression vs. activation, respectively.
Authors: Qianghu Wang; Baoli Hu; Xin Hu; Hoon Kim; Massimo Squatrito; Lisa Scarpace; Ana C deCarvalho; Sali Lyu; Pengping Li; Yan Li; Floris Barthel; Hee Jin Cho; Yu-Hsi Lin; Nikunj Satani; Emmanuel Martinez-Ledesma; Siyuan Zheng; Edward Chang; Charles-Etienne Gabriel Sauvé; Adriana Olar; Zheng D Lan; Gaetano Finocchiaro; Joanna J Phillips; Mitchel S Berger; Konrad R Gabrusiewicz; Guocan Wang; Eskil Eskilsson; Jian Hu; Tom Mikkelsen; Ronald A DePinho; Florian Muller; Amy B Heimberger; Erik P Sulman; Do-Hyun Nam; Roel G W Verhaak Journal: Cancer Cell Date: 2017-07-10 Impact factor: 31.743
Authors: Justin V Joseph; Siobhan Conroy; Kirill Pavlov; Pallavi Sontakke; Tushar Tomar; Ellie Eggens-Meijer; Veerakumar Balasubramaniyan; Michiel Wagemakers; Wilfred F A den Dunnen; Frank A E Kruyt Journal: Cancer Lett Date: 2015-01-12 Impact factor: 8.679
Authors: Roel G W Verhaak; Katherine A Hoadley; Elizabeth Purdom; Victoria Wang; Yuan Qi; Matthew D Wilkerson; C Ryan Miller; Li Ding; Todd Golub; Jill P Mesirov; Gabriele Alexe; Michael Lawrence; Michael O'Kelly; Pablo Tamayo; Barbara A Weir; Stacey Gabriel; Wendy Winckler; Supriya Gupta; Lakshmi Jakkula; Heidi S Feiler; J Graeme Hodgson; C David James; Jann N Sarkaria; Cameron Brennan; Ari Kahn; Paul T Spellman; Richard K Wilson; Terence P Speed; Joe W Gray; Matthew Meyerson; Gad Getz; Charles M Perou; D Neil Hayes Journal: Cancer Cell Date: 2010-01-19 Impact factor: 31.743
Authors: Lin Wang; Husam Babikir; Sören Müller; Garima Yagnik; Karin Shamardani; Francisca Catalan; Gary Kohanbash; Beatriz Alvarado; Elizabeth Di Lullo; Arnold Kriegstein; Sumedh Shah; Harsh Wadhwa; Susan M Chang; Joanna J Phillips; Manish K Aghi; Aaron A Diaz Journal: Cancer Discov Date: 2019-09-25 Impact factor: 38.272
Authors: Toshiro Hara; Rony Chanoch-Myers; Nathan D Mathewson; Chad Myskiw; Lyla Atta; Lillian Bussema; Stephen W Eichhorn; Alissa C Greenwald; Gabriela S Kinker; Christopher Rodman; L Nicolas Gonzalez Castro; Hiroaki Wakimoto; Orit Rozenblatt-Rosen; Xiaowei Zhuang; Jean Fan; Tony Hunter; Inder M Verma; Kai W Wucherpfennig; Aviv Regev; Mario L Suvà; Itay Tirosh Journal: Cancer Cell Date: 2021-06-03 Impact factor: 38.585
Authors: Jinzhou Yuan; Hanna Mendes Levitin; Veronique Frattini; Erin C Bush; Deborah M Boyett; Jorge Samanamud; Michele Ceccarelli; Athanassios Dovas; George Zanazzi; Peter Canoll; Jeffrey N Bruce; Anna Lasorella; Antonio Iavarone; Peter A Sims Journal: Genome Med Date: 2018-07-24 Impact factor: 11.117